Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
A phase 1/2 trial of Elacestrant and Abemaciclib in brain and spinal cord tumours, run by Stemline Therapeutics, Inc., now recruiting.
Overview
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer is a phase 1/2 interventional study registered as NCT05386108 by Stemline Therapeutics, Inc., with 73 participants planned, started 2022-08-31 and due to reach its primary completion in 2026-12. Interventions recorded: Elacestrant and Abemaciclib.
Similar pages
not linked directly; found by shared links- TrialELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
Shares Menarini / Stemline, Elacestrant and the tag pipeline.
- TrialA Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
Shares Menarini / Stemline, Elacestrant and the tag pipeline.
- TrialA Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Shares Menarini / Stemline, Elacestrant and the tag pipeline.
- TrialOpen-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Shares Menarini / Stemline, Elacestrant and the tag pipeline.
- TrialStudy of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialA Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
Shares Brain and spinal cord tumours (all types) and the tag pipeline.
- TrialPhase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Shares Elacestrant, Abemaciclib and the tag pipeline.
- TrialA Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
Shares Menarini / Stemline and the tag pipeline.